Prognostic significance of serum osteopontin levels in small cell lung cancer

BMC Pulm Med. 2020 Sep 1;20(1):235. doi: 10.1186/s12890-020-01242-3.

Abstract

Background: Osteopontin (OPN) is closely related to tumor occurrence and metastasis. This study explored the clinical value of serum OPN levels in small cell lung cancer (SCLC) patients.

Methods: The ELISA method was used to determine the OPN level of 96 SCLC patients before and after first-line chemotherapy, and compared with 60 healthy controls.

Results: The serum OPN level of SCLC patients before treatment was significantly higher than that of the healthy control (P < 0.001). Serum OPN levels were related to disease stage, tumor size, and lymph node metastasis (P = 0.012, 0.034, and 0.037, respectively). Serum OPN level decreased after first-line chemotherapy (P = 0.019), which was related to treatment response (P = 0.011). The serum OPN level was an independent predictor of overall survival.

Conclusions: The serum OPN level can be used as a biomarker to predict treatment response and survival of SCLC patients.

Keywords: Biomarker; Osteopontin; Overall survival; Small cell lung cancer; Treatment responses.

MeSH terms

  • Adult
  • Aged
  • Carcinoma, Non-Small-Cell Lung / blood*
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Female
  • Humans
  • Lung Neoplasms / blood*
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / mortality
  • Male
  • Middle Aged
  • Osteopontin / blood*
  • Prognosis
  • Survival Rate

Substances

  • Osteopontin